Fisher Asset Management Boosts Stake in Halozyme Therapeutics

Firm increases holding in biopharmaceutical company by 7.6% in Q3

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Fisher Asset Management LLC increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.6% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 410,892 shares of the biopharmaceutical company's stock, worth approximately $30.1 million.

Why it matters

Halozyme Therapeutics is a biopharmaceutical company focused on developing drug delivery technologies. The increase in Fisher Asset Management's stake suggests the firm sees long-term potential in Halozyme's business and technology platform.

The details

According to the 13F filing, Fisher Asset Management purchased an additional 29,147 shares of Halozyme Therapeutics during the third quarter. This brings the firm's total ownership stake in the company to 0.35%. Halozyme Therapeutics is developing its ENHANZE® drug delivery technology, which uses a recombinant human hyaluronidase enzyme to facilitate the subcutaneous administration of injectable biologics and small molecules.

  • Fisher Asset Management filed its 13F report for the third quarter on October 15, 2026.

The players

Fisher Asset Management LLC

An investment management firm that oversees over $200 billion in assets.

Halozyme Therapeutics, Inc.

A biopharmaceutical company focused on developing drug delivery technologies, including its ENHANZE® platform.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Fisher Asset Management in Halozyme Therapeutics suggests the firm sees long-term growth potential in the company's drug delivery technologies. As Halozyme continues to develop and commercialize its ENHANZE® platform, its stock could be an attractive investment for institutional investors focused on the biopharmaceutical sector.